Skip to content

Study to Assess the Prognostic Value of the Antithrombin III in the Acute Pancreatitis (AT-PROPANC)

Epidemiologic , Observational, Prospective Study to Assess the Prognostic Value of the Antithrombin III in the Development of Moderate or Severe Acute Pancreatitis (AT-PROPANC)

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02373293
Acronym
AT-PROPANC
Enrollment
400
Registered
2015-02-27
Start date
2015-01-18
Completion date
2017-08-31
Last updated
2017-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pancreatitis

Keywords

Acute pancreatitis

Brief summary

This is an epidemiological, observational, prospective, multicentric study in 400 adult patients admitted to hospital for mild acute pancreatitis to to assess the prognostic value of the antithrombin III in the development of moderate or severe acute pancreatitis.

Detailed description

This is an epidemiological, observational, prospective, multicentric study in 400 adult patients admitted to hospital for mild acute pancreatitis to to assess the prognostic value of the antithrombin III in the development of moderate or severe acute pancreatitis. In the context of clinical practice of general surgery and apparatus digestive services, patients entering with mild acute pancreatitis will be asked to participate in the study and if so, they will sign the informed consent. On admission, demographic and anthropometric data of the patient will be recorded, as well as medical history, patient's admission data and vital signs. Patient's blood will be drawn for analysys and the risk of organ failure will be measured by modified Marshall and Apache II scales. The assessments and procedures performed are the standard practice at the center. At 24 hours (± 3 hours) and at 7 days (or nine days to avoid weekends) after admisison, vital signs will be recorded, laboratory tests will be performed and the risk of organ failure will be measured by modified Marshall and Apache II scales. At discharge of the patient (regardless of when it occurs), the outcome of the acute pancreatitis will be recorded. . Those patients discharged within the first month after admission will be visited or called (according to standard practice at the center) one month after arrival, to record follow-up data, including health condition, readmissions and abdominal pain evaluation by visual analog scale.

Interventions

None listed

Sponsors

Alclinical Research, S.L.
CollaboratorUNKNOWN
Francisco Javier García Borobia
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients diagnosed with mild acute pancreatitis according to seriousness criteria established by Banks et al, 2013. * Patients of either sex aged ≥ 18 years . * Patients who have given their written informed consent

Exclusion criteria

* Patients with exacerbated chronic pancreatitis. * Patients with coagulation disorders (congenital and acquired antithrombin deficiency) . * Patients with liver cirrhosis. * Pregnant patients

Design outcomes

Primary

MeasureTime frameDescription
antithrombin III levels vs maximum seriousness grade of acute pancreatitisAt Admission and at 24hLevels of antithrombin III at admission and at 24h will be related with maximum seriousness grade of acute pancreatitis reached during patient's admission at site by logistic regression models

Secondary

MeasureTime frameDescription
result of modified Marshall and Apache II scalesAdmission and at 24h
antithrombin III levels vs mortalityFrom date of admission until the end of study or date of death from any cause, whichever came first, assessed up to 1 monthLevels of antithrombin III at admission and at 24h will be related with mortality rates by logistic regression models
antithrombin III levels vs organic failureFrom date of admission until the end of study or date of organic failure, whichever came first, assessed up to 1 monthLevels of antithrombin III at admission and at 24h will be related with organic failure rates by logistic regression models
antithrombin III levels vs necrosis and infection ratesFrom date of admission until the end of study or date of necrosis or infection diagnosis, whichever came first, assessed up to 1 monthLevels of antithrombin III at admission and at 24h will be related with necrosis and infection rates by logistic regression models

Countries

Spain

Contacts

Primary ContactFrancisco Javier García Borobia, Dr.
fjgarcia@tauli.cat+34 93 7231010

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026